Novo Nordisk
Novo Nordisk A/Sは、デンマークの多国籍製薬会社で、バッグスベアードに本社を置き、9カ国に生産拠点、5カ国に関連会社または事務所を持つ。Novo Nordiskは大株主であるNovo Holdings A/Sによって支配されており、同社は株式の約28%、議決権株式の過半数（77%）を保有している。
 Headquarters in Bagsværd, デンマーク | |
| Sector | Public |
|---|---|
| |
| Industry | Pharmaceuticals/ja, Health care/ja |
Key people |
|
| Products | |
 102.6 billion kr. (2023) | |
| 83.68 billion kr. (2023) | |
| Total assets | 314.5 billion kr. (2023) |
| Total equity | 106.6 billion kr. (2023) |
| Owner | Novo Holdings A/S (28%) |
Number of employees | 64,319 (end 2023) |
| Website | novonordisk |
Novo Nordiskは医薬品製品およびサービス、特に糖尿病治療医薬品および機器を製造・販売している。主な製品はセマグルチドという薬物で、オゼンピックという商品名で糖尿病の治療に、ウゴービという商品名で肥満症の治療に使用されている。Novo Nordiskはまた、止血管理、成長ホルモン療法、ホルモン補充療法にも携わっている。同社は、レベミル、トレシーバ、ノボログ、ノボリンR、ノボセブン、ノボエイト、ビクトーザなど、さまざまなブランド名で複数の薬物を製造している。
Novo Nordiskは全世界で48,000人以上の従業員を擁し、168カ国で製品を販売している。Novo Nordiskは1989年、1920年代にさかのぼるデンマークの2社が合併して誕生した。Novo Nordiskのロゴは、古代エジプトの神聖な動物のひとつであるアピス牛である。Novo Nordiskは欧州製薬団体連合会（EFPIA）の正会員である。
フォーチュン誌では2010年に25位、2014年には72位にランクインしている。2012年1月、Novo Nordiskはビジネス誌コーポレート・ナイツによって世界で最も持続可能な企業に選ばれ、スピンオフ企業であるノボザイムズは4位に選ばれた。Novo Nordiskはデンマーク最大の製薬会社である。Novo Nordiskの時価総額は、2023年にはデンマークの経済GDPを超え、ヨーロッパで最も高い評価を受けている製薬会社である。
History
1923
Nordisk Insulinlaboratoriumはインスリンの製造を商業化している。
1982–1994
1982年に米国に進出した。
1986年、Novo Industri A/SはFerrosan Groupを買収し、現在は "Novo Nordisk Pharmatech A/S"となった。
1989年、Novo Industri A/S（Novo Terapeutisk Laboratorium）とNordisk Gentofte A/S（Nordisk Insulinlaboratorium）が合併し、Novo Nordisk A/Sとなる。コペンハーゲンのバグスヴェールに本社を置く世界最大のインスリン製造会社である。
1991年、Novo Industri （現NNE A/S）は、Novo Nordiskの社内コンサルタントとして長年活動してきたが、製薬会社に標準的なエンジニアリングサービス（エンド・ツー・エンド・エンジニアリング）を提供するために合併した。
1994年、Novo Nordiskの既存の情報技術部門がNNIT A/Sとして独立した。同社は2004年に完全所有のaktieselskabに転換された。 2015年3月、NNITはナスダック・ノルディックに上場した。
2000–2018
Novoの酵素事業であるNovozymes A/Sは2000年にスピンアウトした。
。
Novoは2013年、ゼリアを7億ドルで買収した。
同年、Novo Nordisk USAはニュージャージー州プレインズボロ・タウンシップの新しい本社オフィスに移転した。この移転は、それまでプレインズボロにあった複数の施設を統合するものであった。
2015年、同社はAblynxと提携し、ナノボディ技術を利用して少なくとも1つの新薬候補を開発すると発表した。
2018年1月、ロイターは、Novoが31億ドルでAblynxの買収を申し出たと報じた。しかし、Ablynxの取締役会は同日、その価格が事業を過小評価していると説明し、この提案を拒否した。最終的にノボ社は48億ドルで入札したSanofiに敗れた。その後、同年、同社はZiylo社を約8億ドルで買収すると発表した。
2020–present
In March 2020, Novo volunteers started testing samples for SARS-CoV-2 with RT-qPCR equipment in the ongoing coronavirus pandemic to increase available test capacity. In June, the business announced it would acquire AstraZeneca's spin-off Corvidia Therapeutics for an initial sum of $725 million (up to a performance-related maximum of $2.1 billion), boosting its presence in cardiovascular diseases. In November, the company announced it would acquire Emisphere Technologies for $1.8 billion, gaining control of a pill-based treatment for diabetes.
In November 2021, Novo announced it would acquire Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion ($38.25 per share).
In September 2022, Novo agreed to acquire Forma Therapeutics for $1.1 billion with the intent to expand its sickle cell disease and rare blood disorders portfolio.
By 2022 the popularity of Novo's Wegovy and Ozempic for weight loss was so great as to significantly increase growth of the entire economy of Denmark. In fact, two-thirds of Denmark’s overall economic growth in 2022 was attributed to the pharmaceutical industry.
The company's profits increased by 45% year over year in the first half of 2023. In August 2023, Novo agreed to acquire the Montreal-headquartered pharmaceutical company, Inversago Pharma for $1 billion and Embark Biotech for up to $500 million. In October 2023, the company announced it would acquire ocedurenone—an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases—from KBP Biosciences for $1.3 billion.
In November 2023, Novo Nordisk announced investment of €2.1 billion in a French production facility to increase the production capacity and manufacturing of its popular anti-obesity medication.
In February 2024, parent company Novo Holdings A/S agreed to acquire Catalent for $16.5 billion. On completion, Novo Nordisk said it would acquire three manufacturing facilities from its parent for $11 billion to scale up production to meet the demand of Wegovy and Ozempic.
In March 2024 Novo Nordisk reached $604B market cap and became 12th most valuable company in the world. Company's stock jumped to a record high after early trial data showed positive results for its new experimental weight loss pill Amycretin.
Acquisition history
- Novo Nordisk A/S
- Xellia (Acq 2013)
- Ziylo (Acq 2018)
- Corvidia Therapeutics (Acq 2020)
- Emisphere Technologies (Acq 2020)
- Dicerna Pharmaceuticals (Acq 2021)
- Forma Therapeutics (Acq 2022)
- Inversago (Acq 2023)
- Embark Biotech (Acq 2023)
Toxicogenomics
Novo Nordisk is involved in government funded collaborative research projects with other industrial and governmental partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of European Federation of Pharmaceutical Industries and Associations and the European Commission.
Diabetic work
.jpg)
Novo Nordisk founded the World Diabetes foundation to save the lives of those affected by diabetes in developing countries and supported a UN (United Nations) resolution to fight diabetes, making diabetes the only other disease along with HIV / AIDS that the UN has a commitment to combat.
Diabetic treatments account for 85% of Novo Nordisk’s business. Novo Nordisk works with doctors, nurses, and patients, to develop products for self-managing diabetes conditions. The DAWN (Diabetes Attitudes, Wishes and Needs) 2001 study was a global survey of the psychosocial aspects of living with diabetes. It involved over 5,000 people with diabetes and almost 4,000 care providers. This study was designed to identify barriers to optimal health and quality of life. A follow-up study completed in 2012 involved more than 15,000 people living with, or caring for, those with diabetes. In response to British findings, a National Action Plan (NAP) was developed, with a multidisciplinary steering committee, to support the delivery of individualised person-focused care in the United Kingdom. The NAP seeks to provide a holistic approach to a diabetic treatment for patients and their families.
The i3-diabetes programme is a collaboration between the King's Health Partners, one of only six Academic Health Sciences Centres (AHSCs) in England, and Novo Nordisk. The programme is a five-year collaboration designed to deliver personalised care that will lead to improved outcomes for people living with diabetes, and more efficient and effective ways of caring for people with diabetes.
Diabetic support advocacy
Novo Nordisk have sponsored the International Diabetes Federation's Unite for Diabetes campaign.
In March 2014, Novo Nordisk announced a partnership program entitled ‘Cities Changing Diabetes,’ which entails combating urban diabetes. Partnership includes University College London (UCL) and supported by Steno Diabetes Center, as well as a range of local partners including healthcare professionals, city authorities, urban planners, businesses, academics and community leaders.
A November 2014 newspaper article, suggested that a recent medical research breakthrough at Harvard University (creating insulin-producing cells from embryonic stem cells) could potentially put Novo Nordisk out of business. Dr Alan Moses, the chief medical officer of Novo Nordisk, commented that the biology of diabetes is incredibly complex, but also that Novo Nordisk's mission is to alleviate and cure diabetes. If this new medical advance "...meant the dissolution of Novo Nordisk, that'd be fine."
In September 2023, Novo Nordisk and UNICEF announced a multi-year expansion of their collaboration to address childhood overweight and obesity.
Research and pipeline
Novo Nordisk was researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies In September 2014, the company announced a decision to discontinue all research in inflammatory disorders, including the discontinuation of R&D in anti-IL-20 for the treatment of rheumatoid arthritis.
In September 2018, it was reported that the company would lay off 400 administrative staff, laboratory technicians and scientists, in Denmark and China in order to concentrate research and development efforts on “transformational biological and technological innovation”.
Controversies
In 2010, Novo Nordisk breached the code of conduct for Association of the British Pharmaceutical Industry (ABPI), by failing to provide information about side-effects of Victoza and by promoting Victoza prior to being granted market authorisation.
In 2013, Novo Nordisk had to pay back 3.6 kr. billion to the Danish tax authorities due to transfer mispricing.
In March 2013, a debate emerged in which scientists questioned whether the incretin class of diabetic medications – the class to which Victoza belongs – had an increased risk of side effects in the pancreas such as pancreatitis and pancreatic cancer. It was concluded that data currently available did not confirm these concerns.
In October 2013, batches of NovoMix 30 FlexPen and Penfill insulin were recalled in some European countries as their analysis had shown that a small percentage of the products in these batches did not meet the specifications for insulin strength.
In September 2017, Novo Nordisk agreed to pay $58.7 million to end a United States Department of Justice probe into the lack of FDA disclosure to doctors about the cancer risk for their diabetic drug, Victoza.
In March 2023, Novo Nordisk was suspended from the ABPI for a period of two years, for engaging in misleading marketing practices that amounted to "bribing health professionals with inducement to prescribe". This is only the eighth time in the last 40 years that ABPI sanctioned a member organization. Due to this, the Royal College of General Practitioners ended their corporate partnerships as it would be in breach of their ethical guidance. The Novo Nordisk General Manager of the UK, Pinder Sahota, chose to resign as President of the ABPI prior to the suspension.
Sponsorships and pitchpeople
Novo Nordisk has sponsored athletes with diabetes, such as Charlie Kimball in auto racing and Team Novo Nordisk in road cycling.
As of the 2010s, Anthony Anderson (star of Black-ish) serves as a pitchman for Novo Nordisk, and featured in the company's television advertisements which aired in the US.
See also
- Captain Novolin
- NNIT (formerly Novo Nordisk IT)
- Novo Nordisk Foundation
- Novo Nordisk Foundation Center for Protein Research
- Repaglinide
- Team Novo Nordisk
External links
- Official website
- Novo Nordisk Inc
- Novo Nordisk Pharmatech A/S
- Business data for Novo Nordisk:
 | この記事は、クリエイティブ・コモンズ・表示・継承ライセンス3.0のもとで公表されたウィキペディアの項目Novo Nordisk(10 March 2024編集記事参照)を素材として二次利用しています。 WB item: |